CGH
PCRX icon

Crossmark Global Holdings’s Pacira BioSciences PCRX Stock Holding History

Crossmark Global Holdings’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,553
Closed -$390K – 1347
2023
Q4 		$390K Sell
11,553
-534
-4% -$15.6K 0.01% 944
2023
Q3 		$380K Buy
12,087
+476
+4% +$17.2K 0.01% 916
2023
Q2 		$415K Sell
11,611
-49
-0.4% -$2.03K 0.01% 930
2023
Q1 		$476K Buy
11,660
+1,404
+14% +$55.9K 0.01% 850
2022
Q4 		$396K Buy
10,256
+594
+6% +$28.9K 0.01% 894
2022
Q3 		$514K Sell
9,662
-191
-2% -$10.6K 0.01% 764
2022
Q2 		$575K Sell
9,853
-50
-0.5% -$3.27K 0.01% 762
2022
Q1 		$756K Buy
9,903
+5,283
+114% +$352K 0.02% 726
2021
Q4 		$278K Sell
4,620
-5,590
-55% -$308K 0.01% 1184
2021
Q3 		$572K Sell
10,210
-90
-0.9% -$5.19K 0.01% 854
2021
Q2 		$625K Sell
10,300
-170
-2% -$10.8K 0.01% 805
2021
Q1 		$734K Buy
10,470
+190
+2% +$13.6K 0.02% 719
2020
Q4 		$615K Buy
10,280
+5,910
+135% +$346K 0.02% 757
2020
Q3 		$263K Buy
4,370
+170
+4% +$9.88K 0.01% 1091
2020
Q2 		$220K Buy
+4,200
New +$176K 0.01% 1191

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Crossmark Global Holdings's PCRX Position: Q1 2024 in Review

Crossmark Global Holdings sold out of Pacira BioSciences (PCRX) in Q1 2024, closing a stake of 11,553 shares — an estimated $390K sold.

Crossmark Global Holdings first reported a position in PCRX in Q2 2020 and held it in 15 quarters. The position peaked at $756K in Q1 2022. 270 funds tracked by Wall St. Rank hold PCRX as of Q1 2024.

  • Crossmark Global Holdings reported no remaining Pacira BioSciences position as of Q1 2024 after selling out during the quarter.
  • Crossmark Global Holdings sold 11,553 Pacira BioSciences shares in Q1 2024, an estimated $390K.
  • Crossmark Global Holdings first reported a position in Pacira BioSciences in Q2 2020 and held it in 15 quarters.
  • Crossmark Global Holdings's Pacira BioSciences position peaked at $756K in Q1 2022.
  • 270 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2024.

Based on Crossmark Global Holdings's 13F filing for Q1 2024, filed 13 May 2024.